Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound technique could spot placental problems early

NCT ID NCT02884297

Knowledge-focused Sponsor: Centre Hospitalier Régional Metz-Thionville Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a special ultrasound with a contrast agent (SonoVue®) can measure blood flow in the placenta during the first three months of pregnancy. Fifty-five women who had already decided to end their pregnancy took part. The goal was to see if this method works better than standard ultrasound for checking placental health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SonoVue® (sulfur hexafluoride contrast agent)
What this could lead to
If successful, this could lead to a new way to measure placental blood flow early in pregnancy, potentially helping to detect problems like preeclampsia or growth restriction.
What could go wrong
This is a small feasibility study in women already scheduled for termination, so results may not apply to ongoing pregnancies. The contrast agent also carries rare risks like allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

55 people

The number who actually took part.

Started

Oct 2016

Finished

Sep 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years and \<65 years, * Gestational Age: 8 SA ≤ gestational age ≤ 8 SA + 6 days or 11 SA ≤ gestational age ≤ 11 SA + 6 days, * BMI ≤40 kg / m², * Having confirmed his request for termination of pregnancy surgically Exclusion Criteria: 1. Any medical contraindication for administration of SonoVue including: * Hypersensitivity to sulfur hexafluoride or any of the other components of SonoVue®, * Women with recent acute coronary syndrome or suffering from an unstable ischemic heart disease, * women having a right-left shunt, severe pulmonary hypertension (pulmonary artery pressure\> 90 mmHg), an uncontrolled systemic hypertension and woman with respiratory distress syndrome 2. Women with risk for IUGR / PE namely: * Previous history of PE or stunting staff * Autoimmune disease, * Chronic Hypertension * Diabetes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pregnancy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pregnancy

Contacts and locations

Locations

  • CHRU de NANCY

    Nancy, 54511, France

  • Chr Metz Thionville

    Metz, 57085, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.